News Expert questions survival benefit of cancer drugs Spending vast sums to extend life by weeks or months may be unethical, says doctor.
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News AZ's Tagrisso first to be funded through new Cancer Drugs Fu... New-look CDF pays for lung drug Tagrisso
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
